表紙
市場調查報告書
商品編碼
1023506

數位生物標記的全球市場的未來展望 (2030年)

Global Digital Biomarker Market Outlook 2030

出版日期: | 出版商: Research Nester | 英文 401 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球數位生物標記的市場規模,2019年約10億4000萬美元,2030年終達到460億美元以上。還有在預測期間內 (2020年∼2030年) 預計以41.22%的年複合成長率成長。市場主要促進因素,是行動醫療應用程式的普及和網路用戶增加,智慧型手機的全球普及,個人的健康維持的興趣增加等。在各系統組件中,預計資料整合系統急速成長。各治療領域中,神經退化性疾病佔最大的佔有率。在各地區中,北美各國為最大市場。

本報告提供全球數位生物標記市場未來趨勢相關分析,市場基本結構和背景情況 (管理體制,主要的推動及阻礙市場要素,技術性背景等),近來的市場主要動向,市場規模趨勢預測 (到2030年),各市場區隔及各地區詳細趨勢,目前市場競爭狀態,主要企業的簡介,產業相關人員的建議等彙整資訊,為您概述為以下內容。

目錄

第1章 市場概要

第2章 調查手法

第3章 摘要整理:全球數位生物標記市場

第4章 數位生物標記的法規:當局的核准途徑

第5章 市場動態分析

  • 促進因素
  • 阻礙因素
  • 市場機會
  • 趨勢

第6章 全球數位生物標記市場:新型冠狀病毒感染疾病 (COVID-19)的影響分析

第7章 全球數位生物標記市場:波特的五力分析

第8章 傳統/數位生物標記:功能概要,新的用途,公開案例

第9章 全球智慧型手機連接數量和,智慧型手機、平板電腦的網路連接平均速度

第10章 全球各部署方式行動資料流量,和各設備流量

第11章 醫療現場的數位生物標記:目前課題

第12章 全球數位生物標記市場

  • 市場區隔
    • 各系統組件 (單位:100萬美元,2019年∼2030年)
    • 各治療領域 (單位:100萬美元,2019年∼2030年)
    • 各用途 (單位:100萬美元,2019年∼2030年)
    • 各開發階段 (單位:100萬美元,2019年∼2030年)
    • 各終端用戶 (單位:100萬美元,2019年∼2030年)

第13章 北美的數位生物標記市場

第14章 歐洲的數位生物標記市場

第15章 亞太地區的數位生物標記市場

第16章 南美的數位生物標記市場

第17章 中東、非洲的數位生物標記市場

第18章 競爭情形

  • ActiGraph LLC
  • Akili Interactive Labs, Inc.
  • AliveCor, Inc.
  • Altoida, Inc.
  • Biogen Inc.
  • ConnectedLife Health Pte Ltd
  • Cambridge Cognition Ltd
  • Evidation Health, Inc.
  • Fitbit, Inc.
  • Happify, Inc.
  • Human API
  • GlaxoSmithKline plc
  • Huma
  • IXICO plc
  • Kinsa Inc.
  • Koneksa
  • Medical Care Corporation
  • Mindstrong Health
  • Koninklijke Philips N.V.
  • Neurotrack Technologies, Inc.
  • Novartis AG
  • ResMed
  • F. Hoffmann-La Roche Ltd
  • Winterlight Labs
  • Verily Life Sciences LLC
目錄

Global Digital Biomarker Market Analysis 2019-2030

Digital biomarkers are consumer generated physiological and behavioral measures that are collected through connected digital devices. The collected data is then used to explain, influence or predict health related outcomes of an individual. The global digital biomarker market is anticipated to grow with a CAGR of 41.22% during the forecast period, i.e., 2020-2030. Factors such as the growing adoption of mobile health applications, increasing number of internet users, growing adoption of smartphone worldwide, and the rise in awareness amongst individuals for maintaining a good health, are anticipated to drive the market growth. The market garnered a revenue of around USD 1040 Million in the year 2019 and is further projected to reach over USD 46000 Million by the end of 2030.

The global digital biomarker market is segmented on the basis of numerous segments, which include segmentation by system component, therapeutic area, development status, end users, and by region. On the basis of system component, the market is segmented into data collection tools and data integration systems, out of which, the data integration systems segment is expected to grow with the highest CAGR of about 42% during the forecast period. The market is also segmented on the basis of therapeutic area into cardiovascular diseases, neurodegenerative disorders, sleep & movement diseases, psychiatric disorders, chronic pain, gastrointestinal diseases, diabetes, respiratory conditions, and others, out of which, the neurodegenerative disorders segment is expected to grab the largest market revenue of over USD 11800 Million by the end of 2030.

On the basis of regional analysis, the market is segmented into North America, Asia Pacific, Europe, South America, and Middle East & Africa, out of which, the market in North America is expected to leading market share throughout the forecast period and further garner a market revenue of close to USD 21 Million by 2030.

Some of the prominent industry leaders in the global digital biomarker market that are included in our report are: ActiGraph LLC, Akili Interactive Labs, Inc., AliveCor, Inc., Altoida, Inc., Biogen Inc., ConnectedLife Health Pte Ltd, Cambridge Cognition Ltd, Evidation Health, Inc., Fitbit, Inc., Happify, Inc., Human API, GlaxoSmithKline plc, Huma, IXICO plc, Kinsa Inc., Koneksa, Medical Care Corporation, Mindstrong Health, Koninklijke Philips N.V., Neurotrack Technologies, Inc., Novartis AG, ResMed, F. Hoffmann-La Roche Ltd, Winterlight Labs, Verily Life Sciences LLC, and others.

Table of Contents

1. Market Introduction

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Assumption

2. Research Methodology

  • 2.1 Research Objective
  • 2.2 Research Process
  • 2.3 Secondary Research
  • 2.4 Market Size Estimation
  • 2.5 Primary Research
    • 2.5.1 Service Providers
    • 2.5.2 Component Manufacturers

3. Executive Summary - Global Digital Biomarker Market

4. Pathway to Regulatory Approval of Digital Biomarkers

5. Analysis of Market Dynamics

  • 5.1 Drivers
  • 5.2 Restraints
  • 5.3 Opportunities
  • 5.4 Trends

6. COVID-19 Impact Analysis on the Global Digital Biomarker Market

7. PORTER'S Five Forces Analysis on the Global Digital Biomarker Market

8. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples

9. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets

10. World Mobile Data Traffic by Deployment Mode & Traffic by Device

11. Current Challenges of Digital Biomarkers in Medical Settings

12. Global Digital Biomarker Market

  • 12.1 Global Digital Biomarker Market Segmentation by:
    • 12.1.1 System Component, 2019-2030F (in USD Million)
    • 12.1.2 Therapeutic Area, 2019-2030F (in USD Million)
    • 12.1.3 Application, 2019-2030F (in USD Million)
    • 12.1.4 Development Status, 2019-2030F (in USD Million)
    • 12.1.5 End User, 2019-2030F (in USD Million)

13. North America Digital Biomarker Market

  • 13.1 North America Digital Biomarker Market Segmentation by:
    • 13.1.1 System Component, 2019-2030F (in USD Million)
    • 13.1.2 Therapeutic Area, 2019-2030F (in USD Million)
    • 13.1.3 Application, 2019-2030F (in USD Million)
    • 13.1.4 Development Status, 2019-2030F (in USD Million)
    • 13.1.5 End User, 2019-2030F (in USD Million)
    • 13.1.6 Country-wise, 2019-2030F (in USD Million)

14. Europe Digital Biomarker Market

  • 14.1 Europe Digital Biomarker Market Segmentation by:
    • 14.1.1 System Component, 2019-2030F (in USD Million)
    • 14.1.2 Therapeutic Area, 2019-2030F (in USD Million)
    • 14.1.3 Application, 2019-2030F (in USD Million)
    • 14.1.4 Development Status, 2019-2030F (in USD Million)
    • 14.1.5 End User, 2019-2030F (in USD Million)
    • 14.1.6 Country-wise, 2019-2030F (in USD Million)

15. Asia Pacific Digital Biomarker Market

  • 15.1 Asia Pacific Digital Biomarker Market Segmentation by:
    • 15.1.1 System Component, 2019-2030F (in USD Million)
    • 15.1.2 Therapeutic Area, 2019-2030F (in USD Million)
    • 15.1.3 Application, 2019-2030F (in USD Million)
    • 15.1.4 Development Status, 2019-2030F (in USD Million)
    • 15.1.5 End User, 2019-2030F (in USD Million)
    • 15.1.6 Country-wise, 2019-2030F (in USD Million)

16. Latin America Digital Biomarker Market

  • 16.1 Latin America Digital Biomarker Market Segmentation by:
    • 16.1.1 System Component, 2019-2030F (in USD Million)
    • 16.1.2 Therapeutic Area, 2019-2030F (in USD Million)
    • 16.1.3 Application, 2019-2030F (in USD Million)
    • 16.1.4 Development Status, 2019-2030F (in USD Million)
    • 16.1.5 End User, 2019-2030F (in USD Million)
    • 16.1.6 Country-wise, 2019-2030F (in USD Million)

17. Middle East & Africa Digital Biomarker Market

  • 17.1 Middle East & Africa Digital Biomarker Market Segmentation by:
    • 17.1.1 System Component, 2019-2030F (in USD Million)
    • 17.1.2 Therapeutic Area, 2019-2030F (in USD Million)
    • 17.1.3 Application, 2019-2030F (in USD Million)
    • 17.1.4 Development Status, 2019-2030F (in USD Million)
    • 17.1.5 End User, 2019-2030F (in USD Million)
    • 17.1.6 Country-wise, 2019-2030F (in USD Million)

18. Competitive Landscape

  • 18.1 ActiGraph LLC
  • 18.2 Akili Interactive Labs, Inc.
  • 18.3 AliveCor, Inc.
  • 18.4 Altoida, Inc.
  • 18.5 Biogen Inc.
  • 18.6 ConnectedLife Health Pte Ltd
  • 18.7 Cambridge Cognition Ltd
  • 18.8 Evidation Health, Inc.
  • 18.9 Fitbit, Inc.
  • 18.10 Happify, Inc.
  • 18.11 Human API
  • 18.12 GlaxoSmithKline plc
  • 18.13 Huma
  • 18.14 IXICO plc
  • 18.15 Kinsa Inc.
  • 18.16 Koneksa
  • 18.17 Medical Care Corporation
  • 18.18 Mindstrong Health
  • 18.19 Koninklijke Philips N.V.
  • 18.20 Neurotrack Technologies, Inc.
  • 18.21 Novartis AG
  • 18.22 ResMed
  • 18.23 F. Hoffmann-La Roche Ltd
  • 18.24 Winterlight Labs
  • 18.25 Verily Life Sciences LLC